A5041853152- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Neuroendocrine Tumor Research Advances
- Medical Imaging and Pathology Studies
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related molecular mechanisms research
- Occupational and environmental lung diseases
- Tracheal and airway disorders
- Pleural and Pulmonary Diseases
- Genetic factors in colorectal cancer
- PI3K/AKT/mTOR signaling in cancer
- Gastric Cancer Management and Outcomes
- Epigenetics and DNA Methylation
- Neuroblastoma Research and Treatments
- Myasthenia Gravis and Thymoma
- Vascular Tumors and Angiosarcomas
- Sarcoma Diagnosis and Treatment
- MicroRNA in disease regulation
- Cancer therapeutics and mechanisms
- Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
Japanese Foundation For Cancer Research
2016-2025
Cancer Institute (WIA)
2016-2025
The Cancer Institute Hospital
2015-2024
Chugai Pharma (United States)
2015
Otsuka (Japan)
2015
Princess Takamatsu Cancer Research Fund
2015
Daiichi Sankyo (United States)
2015
National Defense Medical College
2010
Fukuoka University
1991-2006
Miyazaki Prefectural Hospital
2003-2004
The anaplastic lymphoma kinase (ALK) fusion oncogene is observed in 3%-5% of non-small cell lung cancer (NSCLC). Crizotinib and ceritinib, a next-generation ALK tyrosine inhibitor (TKI) active against crizotinib-refractory patients, are clinically available for the treatment ALK-rearranged NSCLC multiple ALK-TKIs currently under clinical evaluation. These exhibit robust activity patients; however, emergence ALK-TKI resistance restricts therapeutic effect. To date, various secondary mutations...
Abstract Mutations in the ALK gene are detectable approximately 40% of ALK-rearranged lung cancers resistant to inhibitors. Although epithelial-to-mesenchymal transition (EMT) is a mechanism resistance various targeted drugs, its involvement inhibitor largely unknown. In this study, we report that both ALK-mutant L1196M and EMT were concomitantly detected single crizotinib-resistant lesion patient with cancer. Digital PCR analyses combined microdissection after IHC staining for markers...
TROP2 is a transmembrane glycoprotein that overexpressed in various cancers. Emerging evidence suggests TROP2-targeting therapies are efficacious and safe patients with multiple prior treatments. promising target for lung cancer treatment; however, little known regarding the association of expression clinicopathological/molecular features, including prognosis, cancer. We examined consecutive cases adenocarcinoma, squamous cell carcinoma (SqCC), high-grade neuroendocrine tumor (HGNET)...
To diagnose small cell lung carcinoma (SCLC), neuroendocrine (NE) phenotype markers such as chromogranin A, synaptophysin, and CD56 are helpful. However, because they dispensable, SCLCs occur without apparent NE phenotypes. Insulinoma-associated protein 1 (INSM1) is a transcription factor for differentiation has emerged single practical marker SCLC. Using the surgical samples of 141 pulmonary tumors (78 SCLCs, 44 large carcinomas, 19 carcinoids), 246 non-NE we examined immunohistochemical...
Abstract Context.—Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are molecular-targeted drugs that innovatively effective for non–small cell lung carcinomas with EGFR mutations. Epidermal is a transmembrane forming dimers on ligand binding. These then stimulate signals by activating autophosphorylation through activity. Autophosphorylation triggers intracellular pathways facilitating malignant conversion. The most clinically advanced inhibition strategies include...
Programmed death-ligand 1 is an immune modulator that promotes immunosuppression by binding to programmed death-1 of T-lymphocytes. Whereas expression has been shown be associated with the clinical response anti-programmed antibody, association tumor clinicopathological/molecular features and prognosis remains inconclusive in lung adenocarcinoma. We therefore examined adenocarcinoma.Using tissue microarrays 268 consecutive cases adenocarcinoma, we evaluated immunohistochemistry....
Immune checkpoint therapy targeting the PD-1/PD-L1 axis is a potentially novel development in anticancer and has been applied to clinical medicine. However, there are still some problems, including relatively low response rate, innate mechanisms of resistance against immune blockades, absence reliable biomarkers predict responsiveness. In this study vitro vivo models, we demonstrate that PD-L1-vInt4, splicing variant PD-L1, plays role as decoy anti-PD-L1 antibody treatment. First, showed...
Abstract Programmed death‐ligand 1 ( PD ‐L1) promotes immunosuppression by binding to ‐1 on T lymphocytes. Although tumor ‐L1 expression is a potential predictive marker of clinical response anti‐ ‐1/ therapy, little known about its association with clinicopathological features, including prognosis, in high‐grade neuroendocrine tumors HGNET s), small‐cell lung carcinoma SCLC ) and large‐cell LCNEC ), the lung. We immunohistochemically examined membranous 115 consecutive surgical cases (74 41...
Hyalinizing clear cell carcinoma of the bronchial glands is a very rare tumor. Since only five reports describing six tumors have been published to date, little known about specific histologic findings and clinical features. Because its rarity, hyalinizing has not described in latest WHO classification pulmonary yet. Here we present three cases carcinomas, confirmed by both fluorescence situ hybridization (FISH) RT-PCR, focusing on immunohistochemical characteristics comparison with salivary...
Small-cell lung carcinoma (SCLC) is a type of cancer with neuroendocrine differentiation and poor prognosis that widely believed to arise in the central lung. Thyroid transcription factor-1 (TTF-1) peripheral marker adenocarcinoma also highly expressed SCLC. In this study, we examined whether SCLC really central-type tumor relationship between location, TTF-1 expression Ninety six SCLCs, diagnosed from biopsies or surgical materials, for which detailed computed tomography (CT) images were...
Background: The efficacy of local therapies for lung cancer patients with postoperative oligo-recurrence has been reported. However, whether should be chosen over molecular targeted driver mutations remains controversial. Therefore, we aimed to investigate the optimal initial treatment strategy in mutations. Methods: Among 2152 adenocarcinoma who underwent surgical resection at our institute between 2008 and 2020, 66 experienced after surgery were treated or molecularly therapy as an...